longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Enlivex

ENLV

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 0.00, above the reasonable range, cheaper than 10.21% of the time in the past 5 years, and the industry ranks 1/603, the industry Median -2.26.

0.0028xP/E
$0.51Stock price
$182.43Earnings per share
0.0028xP/E
Stock price$0.51Earnings per share$182.43

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-1.78x
Typical range
-3.68x–-1.08x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GRFSUSGRIFOLS SA
9.71x42.44%$5.09B
ACADUSAcadia Pharma
9.30x73.45%$3.54B
PURRUSHyperliquid Strategies
9.33x84.74%$2.39B
ADMAUSAdma Biologics
13.42x35.42%$2.27B
AUPHUSAurinia Pharma
7.00x54.40%$2.20B
LKFTUSLakefront Biotherapeutics
2.80x86.19%$1.94B
ANABUSAnaptysbio
5.80x1,051.46%$1.52B
VORUSVor BioPharma
1.73x89.77%$1.08B
MGTXUSMeiraGTx
13.51x122.03%$1.07B
ABUSUSArbutus Pharma
6.25x533.09%$957.13M
RIGLUSRigel Pharma
2.86x83.91%$922.04M
BVNRYUSBavarian Nordic A/S
3.50x--$839.93M
IRWDUSIronwood Pharma
5.24x715.55%$680.79M
AGENUSAgenus
4.62x--$424.54M
CUVLUSClinuvel Pharmaceuticals
12.65x--$289.96M
QTTBUSQ32 Bio
8.13x162.67%$274.77M
CGENUSCompugen
6.27x173.68%$220.71M
PLXUSProtalix Biotherap
11.44x400.00%$216.74M
VXRTUSVaxart
2.89x328.57%$111.33M
RLYBUSRallybio
1.99x131.45%$90.54M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.